Enzo Biochem Total Liabilities 2010-2022 | ENZ

Enzo Biochem total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Enzo Biochem Annual Total Liabilities
(Millions of US $)
2021 $45
2020 $54
2019 $21
2018 $21
2017 $19
2016 $22
2015 $26
2014 $27
2013 $25
2012 $20
2011 $21
2010 $18
2009 $16
Enzo Biochem Quarterly Total Liabilities
(Millions of US $)
2022-04-30 $42
2022-01-31 $44
2021-10-31 $41
2021-07-31 $45
2021-04-30 $49
2021-01-31 $50
2020-10-31 $54
2020-07-31 $54
2020-04-30 $54
2020-01-31 $46
2019-10-31 $47
2019-07-31 $21
2019-04-30 $20
2019-01-31 $22
2018-10-31 $19
2018-07-31 $21
2018-04-30 $19
2018-01-31 $20
2017-10-31 $20
2017-07-31 $19
2017-04-30 $18
2017-01-31 $19
2016-10-31 $22
2016-07-31 $22
2016-04-30 $24
2016-01-31 $26
2015-10-31 $27
2015-07-31 $26
2015-04-30 $24
2015-01-31 $25
2014-10-31 $27
2014-07-31 $27
2014-04-30 $25
2014-01-31 $24
2013-10-31 $25
2013-07-31 $25
2013-04-30 $22
2013-01-31 $22
2012-10-31 $21
2012-07-31 $20
2012-04-30 $19
2012-01-31 $20
2011-10-31 $20
2011-07-31 $21
2011-04-30 $19
2011-01-31 $20
2010-10-31 $19
2010-07-31 $18
2010-04-30 $14
2010-01-31 $22
2009-10-31 $16
2009-07-31 $16
2009-04-30 $18
2009-01-31 $17
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.104B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00